RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CXCR6 表达预测肌层浸润性膀胱癌的预后和免疫治疗获益
英文原题：CXCR6 expression predicts prognosis and immunotherapeutic benefit in muscle-invasive bladder cancer.
查看英文原题
CXCR6 expression predicts prognosis and immunotherapeutic benefit in muscle-invasive bladder cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
我们的研究结果强调 CXCR6 是预测 MIBC 预后和免疫治疗反应的关键生物标志物。
研究思路结论见上方概要
背景
越来越多的证据表明，CXC趋化因子受体6（CXCR6）参与肿瘤进展和肿瘤免疫调节。然而，其在肌层浸润性膀胱癌（MIBC）中的作用仍很大程度上未被探索。
方法
分析了来自TCGA的391例MIBC患者数据、GEO的212例患者数据、本中心的131例患者数据、IMvigor210队列的195例患者数据，以及9例膀胱癌患者的单细胞RNA测序（scRNA-seq）数据（GSE222315）。此外，还利用GEPIA 2、TISCH2、TIMER2.0和UALCAN平台的数据，探讨了CXCR6在MIBC中的预后和免疫治疗意义。
结果
我们观察到膀胱癌肿瘤中CXCR6表达显著降低，并与肿瘤分期和分级相关。CXCR6低表达与TCGA队列中较差的无复发生存期（RFS）和总生存期（OS）相关，这一发现在meta-GEO数据集和我们中心的队列中均得到验证。多因素分析证实，CXCR6低表达是较差OS和RFS的独立预测因子。我们开发了一个包含CXCR6表达和其他独立预后因素的列线图，以准确预测3年和5年OS。基因集富集分析表明，免疫激活相关通路在CXCR6高表达的肿瘤中显著富集。CIBERSORT分析显示，在TCGA中CXCR6表达与CD8+ T细胞、CD4+ T细胞、活化NK细胞、M1巨噬细胞和活化树突状细胞呈正相关，这些发现经TIMER2.0进一步验证。scRNA-seq数据显示CXCR6主要表达于T细胞和NK细胞，并通过CXCR6-CXCL16轴促进T/NK-髓系细胞相互作用。重要的是，CXCL16+巨噬细胞和树突状细胞招募CXCR6+ T细胞和NK细胞，这些细胞表现出增强的细胞毒性，从而放大抗肿瘤免疫。在临床上，在IMvigor210免疫治疗队列中，较高的CXCR6表达与改善的抗PD-L1治疗结局相关。
展开英文摘要原文
BACKGROUND
Increasing evidence suggests that the CXC chemokine receptor 6 (CXCR6) is involved in tumor progression and the regulation of tumor immunity. However, its role in muscle-invasive bladder cancer (MIBC) remains largely unexplored.
METHODS
Data from 391 MIBC patients in the TCGA, 212 patients from GEO, 131 patients from our center, 195 patients in the IMvigor210 cohort, and single-cell RNA sequencing (scRNA-seq) data from 9 bladder cancer patients (GSE222315) were analyzed. Additionally, data from the GEPIA 2, TISCH2, TIMER2.0, and UALCAN platforms were utilized to investigate the prognostic and immunotherapeutic significance of CXCR6 in MIBC.
RESULTS
We observed that CXCR6 expression was significantly reduced in bladder cancer tumors and correlated with tumor stage and grade. Low CXCR6 expression was associated with poor recurrence-free survival (RFS) and overall survival (OS) in the TCGA cohort, a finding validated in both the meta-GEO dataset and our center's cohort. Multivariate analysis confirmed that low CXCR6 expression was an independent predictor of poor OS and RFS. A nomogram incorporating CXCR6 expression and other independent prognostic factors was developed to accurately predict 3- and 5-year OS. Gene set enrichment analysis indicated that immune activation-related pathways were significantly enriched in tumors with high CXCR6 expression. CIBERSORT analysis revealed that CXCR6 expression was positively correlated with CD8+ T cells, CD4+ T cells, activated NK cells, M1 macrophages, and activated dendritic cells in TCGA, findings further validated by TIMER2.0. scRNA-seq data showed that CXCR6 was predominantly expressed in T and NK cells and facilitated T/NK-myeloid interaction via the CXCR6-CXCL16 axis. Importantly, CXCL16+ macrophages and dendritic cells recruited CXCR6+ T and NK cells, which exhibited enhanced cytotoxicity, thereby amplifying anti-tumor immunity. Clinically, in the IMvigor210 immunotherapy cohort, higher CXCR6 expression was associated with improved anti-PD-L1 therapeutic outcomes.
CONCLUSION
Our findings highlight CXCR6 as a critical biomarker for predicting prognosis and immunotherapeutic response in MIBC.
论文信息
- 作者
- Lu X、Ge LP、Liu Z、Zhu Y、Ye D、Chang Y
- 单位
- Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.China
- 期刊
- Frontiers in oncology2024
- 原文标识
- PubMed 39588301 · DOI 10.3389/fonc.2024.1498579
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →